Abstract
The presence of numerous axon-inhibitory molecules limits the capacity of injured neurons in the adult mammalian central nervous system (CNS) to regenerate damaged axons. Among others, chondroitin sulphate proteoglycans (CSPGs) enriched in glycosaminoglycan (GAG) chains, acting intracellularly via Rho GTPase activation and cytoskeletal modification, prevent axon re-growth after injury. However, axon regeneration can be induced by modulating the extrinsic environment or the intrinsic neural response to axon extension. Among other strategies, the use of chondroitinase ABC (ChABC) to degrade GAGs and decrease CSPG-associated inhibition has been analyzed. Recent reports have extended the use of this enzyme, in combination with cell transplantation or pharmacological treatment. The steady advances made in these combinations offer promising perspectives for the development of new therapies to repair the injured nervous system.
Keywords: Chondroitin sulphate proteoglycans, axon regeneration, chondroitinase ABC, glial scar, Schwann cells, olfactory ensheathing glia, neural stem cells
Current Pharmaceutical Design
Title: Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC
Volume: 13 Issue: 24
Author(s): J.A. Del Rio and E. Soriano
Affiliation:
Keywords: Chondroitin sulphate proteoglycans, axon regeneration, chondroitinase ABC, glial scar, Schwann cells, olfactory ensheathing glia, neural stem cells
Abstract: The presence of numerous axon-inhibitory molecules limits the capacity of injured neurons in the adult mammalian central nervous system (CNS) to regenerate damaged axons. Among others, chondroitin sulphate proteoglycans (CSPGs) enriched in glycosaminoglycan (GAG) chains, acting intracellularly via Rho GTPase activation and cytoskeletal modification, prevent axon re-growth after injury. However, axon regeneration can be induced by modulating the extrinsic environment or the intrinsic neural response to axon extension. Among other strategies, the use of chondroitinase ABC (ChABC) to degrade GAGs and decrease CSPG-associated inhibition has been analyzed. Recent reports have extended the use of this enzyme, in combination with cell transplantation or pharmacological treatment. The steady advances made in these combinations offer promising perspectives for the development of new therapies to repair the injured nervous system.
Export Options
About this article
Cite this article as:
J.A. Del Rio and E. Soriano , Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC, Current Pharmaceutical Design 2007; 13 (24) . https://dx.doi.org/10.2174/138161207781368639
DOI https://dx.doi.org/10.2174/138161207781368639 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Interpretation of Drug Susceptibility Tests in Tuberculosis
Current Respiratory Medicine Reviews Frontier View on Nanotechnological Strategies for Neuro-therapy
Current Drug Metabolism IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Current Advances in the Identification and Characterization of Putative Drug and Vaccine Targets in the Bacterial Genomes
Current Topics in Medicinal Chemistry Overview of Congenital Infections: The Prominence of Cytomegalovirus
Infectious Disorders - Drug Targets Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design New Insights into the Immune Response to Pneumococci
Current Respiratory Medicine Reviews Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Dementia Etiologies and Remedies in Traditional Persian Medicine; A Review of Medicinal Plants and Phytochemistry
Current Drug Metabolism Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology Analysis of Nucleic Acids and Proteins in Capillary Electrophoresis and Microchip Capillary Electrophoresis Using Polymers as Additives of the Background Electrolytes
Current Analytical Chemistry Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Virtual Screening for the Development of New Effective Compounds Against Staphylococcus aureus
Current Medicinal Chemistry Naturally Occurring and Synthetic Imidazoles: Their Chemistry and Their Biological Activities
Current Medicinal Chemistry Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents